Tommy Broughan (Dublin Bay North, Independent)
Link to this: Individually | In context | Oireachtas source

361. To ask the Minister for Health further to Parliamentary Question No. 238 of 18 October 2018, when the rare diseases technology review committee will begin assessing and reporting on orphan medicinal products; and if he will make a statement on the matter. [47767/18]

Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines , in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.

Tommy Broughan (Dublin Bay North, Independent)
Link to this: Individually | In context | Oireachtas source

362. To ask the Minister for Health further to Parliamentary Question Nos. 238 and 670 of 18 October 2018, the reason the rare diseases technology review committee does not have a direct input into the NCPE health technology assessment process; if the committee will be permitted to replicate to the Scottish PACE model to have a direct input into the pharmacoeconomic evaluation of orphan medicinal products; and if he will make a statement on the matter. [47768/18]

Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.